Summary
Knowledge and publications in international high impact-factor journals (in the field of cancer and immunology). Reports of clinical trial outcomes with immunomonitoring results should result in reports submitted to the top clinical journals, either general, or specialized in oncology, given the expected efficacy and the novelty of the PROCROP approach. It is expected that the whole consortium will publish a total number of 8-15 papers, including reviews.
More information & hyperlinks